Appendix A

NCCID TB Program Performance Indicators Meeting Worksheet - A Compilation of Performance Indicators across Canadian and International Sources

This worksheet and resource was created to support TB program performance indicator prioritization by meeting participants. Working in population-specific groups, participants reviewed the attached list of 105 indicator priorities compared across eight Canadian and international sources of TB program performance measurement guidance. Participants were asked to indicate which indicators were priorities for the programs, sub-populations, and specific communities that they serve. They were also asked to discuss and record information on key considerations for each indicator including potential definitions (numerators and denominators), key stratifiers, challenges to implementation (feasibility and robustness), and possible solutions to those challenges. Participants were asked to fill in any gaps and add in indicators of interest if they did not exist in the compiled list.

Worksheet for Discussions - TB Program Performance Indicators Across Canadian and International Source Documents

	PHN	FNIHB	Heffernan/Long	Fanning/Orr	WHO	USA-CDC	England	Australia
	Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
Incidence and Inequalities		*Italicized indicators represent potential TB program objectives and performance tagets from PHN*						
Overall and Subpopulation	National Incidence Rate	Number of newly reported cases of **active TB** (new and re-treatment cases)	Incidence	TB Case Incidence	TB Incidence, Prevalence, and Mortality	TB Incidence Rate	TB incidence per 100,000 population. Three year **rolling average** for local levels	Incidence of TB
Pediatric			Proportion of **pediatric cases** (< 5 years)			Incidence of TB disease among **children younger than 5 years of age.**	TB incidence per 100,000 population in UK born **children aged under fifteen years.**	
Respiratory/Non-Respiratory		Number of newly reported cases of **respiratory** (primary, pulmonary, other) and **non-respiratory TB**						
Drug-Resistance	Acquired **drug resistance rate** (target 0%)	Number of newly reported cases of **drug-resistant TB** *Acquired drug resistance rate (target 0%)*					Number and proportion of **culture confirmed TB cases** with **any first line drug resistance.** Annual number and proportion of culture confirmed TB **cases with MDR-TB.**	Incidence and **characteristics** of **drug resistant** TB acquired **within Australia.** Incidence and **characteristics** of **drug resistant** TB in **migrants.**
HIV Co-Infection		Number of newly reported new cases of **active TB** who were also **co-infected with HIV**						
Higher-Risk Groups - Enhanced								Incidence and **Characteristics of TB** in **higher risk groups** (overseas born persons; healthcare workers; irregular maritime arrivals).
Health care-acquired								Number of **cases** of TB **acquired** within Australian **health care institutions/ laboratories**
Inequalities							Slope index of **inequalities (SII) in TB rates** (use index of deprivation score)	
Lab Reporting								
Timely Lab Arrival	Turnaround **time** between specimen **collection** and **arrival** at the **laboratory** (target of 24 hours)	*Turnaround time between specimen collection and arrival at laboratory (target of 24 hours)*						
Timely Smear	Turnaround **time** between **specimen receipt** and AFB **smear microscopy** (target 24 hours)	*Turnaround time between receipt of specimen and AFB smear microscopy (target of 24 hours)*						

	PHN	**FNIHB**	**Heffernan/Long**	**Fanning/Orr**	**WHO**	**USA-CDC**	**England**	**Australia**
	Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
Timely NAAT	Turnaround **time** between smear result and **Nucleic acid amplification testing** for M. tuberculosis complex detection (target 24 hours)	*Turnaround time between smear result and NAAT test for M. Tuberculosis complex detection (target of 24 hours).*	Turn-around **time (NAAT)**			For TB patients with respiratory specimens positive for MTBC by **nucleic acid amplification (NAA)**, the proportion **reported** by the laboratory **within 6 days** from the date the **specimen was collected**.		
Timely Culture	Turn around time for broth cultures (target of up to 6 weeks) and for solid media cultures (target of up to 8 weeks) and bacteriological diagnosis by culture from time specimen received	*Turn around time for broth cultures (target of up to 6 weeks) and for solid media cultures (target of up to 8 weeks) and bacteriological diagnosis by culture from time specimen received*	Turn-around **time (Culture)**			For TB patients with **cultures** of respiratory specimens identified with M. tuberculosis complex (MTBC), the **proportion reported** by the laboratory **within 25 days** from the date the **specimen was collected.**		
Culture-confirmation						For TB **patients** ages 12 years or older with a pleural or respiratory site of disease, the **proportion** who have a **sputum culture result reported**.	Number and proportion of pulmonary **TB cases** that were **culture confirmed.**	Proportion of TB notifications **confirmed by** microbiological **laboratory diagnosis.**
Genotyping			Proportion of **culture-positive cases with genotyping**			For TB patients with a **positive culture** result, increase the proportion who have a **MTBC genotyping result reported**.		
Species Identification-time	Turnaround time between specimen receipt and **identification of mycobacterial species** (target of 21days)	*Turnaround time from specimen receipt to identification of mycobacterial species (target of 21 days)*						
DST			Proportion of **culture-positive cases with DST**		Percentage of all TB patients for whom results of **drug susceptibility testing** were available	For TB patients with positive culture results, the proportion who have initial **drug-susceptibility results reported.**	Number and proportion of **culture confirmed** TB cases with **drug susceptibility testing** reported for the **four first line agents**.	Proportion of **culture-confirmed cases** that undergo **drug susceptibility testing.**
DST-time	Turnaround time between positive culture and primary **susceptibility testing** (target of 7 to 14 day)	*Turnaround time between positive culture and primary susceptibility testing (target of 7 to 14 day)*						**Time** to **identification** of **drug resistant TB.**
Culture-during treatment			Proportion of smear-positive pulmonary cases with **sputum culture** and **CXR,** end of **initial phase** of **treatment** Proportion of smear-positive pulmonary cases with **sputum culture** and **CXR,** end of **continuation phase** of **treatment**					
Report Back-time	Turnaround time between test completion and reporting of all test results both electronically and hard copy (targets of 24 to 48 hours respectively)	*Turnaround time between test completion and reporting of all test results both electronically and hard copy (targets of 24 to 48 hours respectively)*		Turnaround **time** for **sputum smears** to be **reported back** to ordering staff/facility Proportion of **smears reported** back **within 48 hours of collection**				Proportion of **laboratories meeting** the **recommended** turn around **time.**
Diagnostic Delay								Proportion of **cases** with a **diagnostic delay** of greater than 1 month.
Case Management and Treatment								

	PHN	FNIHB	Heffernan/Long	Fanning/Orr	WHO	USA-CDC	England	Australia
	Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
Early Diagnosis-Smear positive				Percentage of pulmonary **TB cases** that are **smear positive**				
Early Diagnosis-symptoms-to-treatment				Proportion of cases where mean and median **time** from **onset of symptoms** to **onset of therapy** is **less than 4 months**			Number and proportion of pulmonary TB cases **starting treatment within two months** and **four months** of **symptom** onset.	
Treatment Initiation	Proportion of cases where treatment is **started with 4 or more anti-TB drugs** until drug sensitivity test results are available, unless there are current local drug sensitivity data showing that resistance is not a risk (target ≥ 90% of cases)	*Proportion of cases where treatment is started with 4 or more anti-TB drugs until drug sensitivity test results are available, unless there are current local drug sensitivity data showing that resistance is not a risk (target ≥ 90% of cases)*	i) Proportion of **Canadian-born cases**/w no past hx TB **started** on a **minimum of 3 drugs** ii) Proportion of **foreign-born cases**/w no past hx TB **started** on a **minimum of 4 drugs**			For patients whose **diagnosis is likely** to be TB disease, the proportion who are **started on the recommended initial 4-drug regimen.**		
Timely Treatment Initiation	Proportion of cases **started** on anti-TB drugs **within 48 hours of diagnosis** (target ≥95%)	*Proportion of cases started on anti-TB drugs within 48 hours of diagnosis (target ≥ 95%)*	Proportion of smear-positive pulmonary cases **starting treatment within 72 h of NAAT**	Proportion of patients who are **diagnosed** with TB (clinically or microbiologically) that **start treatment within 48 hours** of **diagnosis**		For TB patients with positive acid-fast bacillus (AFB) sputum smear results, the proportion who **initiated treatment within 7 days of specimen collection.**		
Sputum Culture Conversion	Proportion of culture-positive, drug-sensitive respiratory cases with **sputum culture conversion** (target ≥ 80% have three consecutive negative sputum cultures **within 60 days** of treatment initiation)	*Proportion of culture-positive, drug-sensitive respiratory cases with sputum culture conversion (target ≥ 80% have three consecutive negative sputum cultures within 60 days of treatment initiation)*		**Sputum Culture Conversion** - Proportion of patients with culture positive sputum that are sputum negative **within 4 months** of treatment initiation		For TB patients with **positive sputum culture** results, the proportion who have documented **conversion** to negative results **within 60 days** of treatment initiation.		
Treatment Completion	Proportion of cases with **treatment success** (cure or completion) **within 12 months** of treatment initiation for patients who did not die or transfer out during treatment (target ≥ 90% of cases)	Number of TB cases (active and re-treatment) diagnosed in (year) who **completed treatment** (including cured) **within one year** of treatment start date *Proportion of cases with treatment success (cure or completion) within 12 months of treatment initiation for patients who did not die or transfer out during treatment (target ≥ 90% of cases)*	Proportion of smear-positive pulmonary cases that **complete treatment within 12 months**	Proportion of patients with newly diagnosed TB, for who 12 months or less of treatment is indicated, who **complete treatment within 12 months**	Tuberculosis **treatment success rate**	For patients with newly diagnosed TB disease for whom 12 months or less of treatment is indicated, the proportion who **complete treatment within 12 months.**	Number and proportion of **drug sensitive TB cases** who had **completed** a full course of **treatment by 12 months.**	Proportion of **successful treatment of TB.**
Lost-to-follow up							Number and proportion of **drug sensitive TB cases** that were **lost to follow up** at last reported outcome.	
Left-treatment		Number of TB cases diagnosed in (year) who **transferred out before treatment completion** within one year of treatment start date						
TB Deaths		Number of TB cases diagnosed in (year) who **died before or during treatment** within one year of treatment start date Number of **deaths** - TB was a **direct cause** Number of **deaths** - TB **contributed,** but was not the cause of death Number of **deaths** - **had TB**, but did not contribute to death	Proportion with **TB-related death of preceding years' cases**				Number and proportion of **drug sensitive TB cases** that had **died** at **last reported outcome.**	

	PHN Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	**FNIHB** First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	**Heffernan/Long** Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	**Fanning/Orr** Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	**WHO** World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	**USA-CDC** CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	**England** Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	**Australia** National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
Re-treatment/ Relapse	**Re-treatment rate within two years** after the end of previous treatment in Canada (target ≤3%)	*Re-treatment rate within two years after the end of previous treatment in Canada (target ≤ 3%)*		Proportion of **cases per year** that are relapsed (**re-treatment cases**)				Proportion of **cases** initially treated in Australia who **relapse within 5 years of treatment.**
Drug-Resistant Treatment Initiation					Percentage of patients with **drug-resistant TB** enrolled **on second-line treatment**			
Drug-Resistant Treatment Outcome							Number and proportion of **drug resistant** TB cases who had **completed treatment at 24 months**. Number and proportion of **drug resistant** TB cases who were **lost to follow up** at last reported outcome. Number and proportion of **drug resistant** TB cases who had **died** at last reported outcome	
HIV - Treatment					Percentage of **HIV-positive** TB patients on **anti-retroviral therapy**			
DOT	Proportion of **cases** treated by standard or enhanced **directly observed therapy (DOT)** (target ≥90% of cases)	*Proportion of cases treated by standard or enhanced directly observed therapy (DOT) (target ≥90% of cases)*		Proportion of cases that are **treated by DOT** **Proportion of TB-HIV co-infected cases that are treated by DOT**				
Underserved Populations							Number and proportion of drug sensitive **TB cases with at least one social risk factor** who **completed treatment within 12 months**. Proportion of TB **patients with social risk factors** recorded who received **enhanced case management.** (*In development)	
HIV Serologic Testing	Proportion of cases where **HIV status known and reported** on PHAC Active TB Case Report Form (target ≥90% of cases by 2015)	*Proportion of cases where HIV status known and reported on PHAC Active TB Case Report Form (target ≥90% of cases by 2015)*	Proportion **HIV tested**	Proportion of TB cases that have **HIV testing** and have the **results reported** provincially and federally	Proportion of TB patients **screened for HIV**	Proportion of TB patients who have a **positive or negative HIV test result reported**	Number and proportion of TB cases **offered an HIV test.**	Proportion of TB cases with a **recorded HIV status.**
Contacts								
Contact Identification	**Proportion** of infectious **TB cases** where **initial list of contacts** is **completed** within **seven** calendar **days** (target 100%)	**Total number of reported contacts** of active TB cases diagnosed in (year) *Proportion of infectious TB cases where initial list of contacts is completed within seven calendar days (target 100%)*		**Contact list** for each infectious case is **completed within 7 days of diagnosis** of index case		**Proportion** of TB patients with **positive AFB sputum-smear** results, who have **contacts elicited.**	**Proportion** of pulmonary **TB cases** who had **close contacts identified** (*In development)	

	PHN Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	**FNIHB** First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	**Heffernan/Long** Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	**Fanning/Orr** Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	**WHO** World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	**USA-CDC** CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	**England** Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	**Australia** National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
Contacts - Close		Number of **close contacts** of active TB cases diagnosed in (year) Number of **Other Contacts (not close)** of active TB cases diagnosed in (year)						
Contact Examination		Of the total number of reported **contacts** of active TB cases diagnosed in [year], the number having no known past history of TB or LTBI (positive TST/IGRA), who were **screened for LTBI**	Proportion of close **contacts** of smear-positive pulmonary cases **completely assessed** (< 5 years of age and ≥ 5 years of age)		**Percentage** of eligible **index cases** of TB for which **contact investigations** were undertaken.	Proportion of **contacts** to sputum AFB smear-positive TB cases, who are **examined for infection and disease.**	Proportion of identified **close contacts** of pulmonary TB cases that were **evaluated.** *(*In development)*	
Contacts - LTBI Identification		Of the number of **contacts screened** for LTBI above, the number with a new positive TST/IGRA or TST/IGRA conversion (i.e., number of newly **identified LTBI)**						
Contacts - LTBI Treatment Recommended		Of the number of **contacts** with a new **positive** TST/IGRA or TST/IGRA **conversion** above, the number **recommended for treatment of LTBI**	Proportion of close **contacts** with new **positive** TST/TST **conversion recommended TX LTBI** (< 5 years of age and ≥ 5 years of age)					
Contacts - LTBI Treatment Acceptance		Of the number of **contacts recommended** for treatment of LTBI above, **the number who accepted treatment for LTBI**		Percentage of client **acceptance of** offered prophylaxis				
Contacts - LTBI Treatment Initiation	Proportion of contacts with a **diagnosis of LTBI** who **begin treatment** (target ≥ 80%)	Of the number of **contacts accepting** treatment of LTBI above, the number who **started** treatment Of the number of **contacts accepting** treatment of LTBI above, the **number (without contraindications** to INH or RMP) **who started treatment** *Proportion of contacts diagnosed with LTBI who begin treatment (target ≥ 80%)*	Proportion of close **contacts** recommended TX LTBI, who **start treatment** (< 5 years of age and ≥ 5 years of age)		Percentage of eligible **people living with HIV** and **children** aged **under-five who are contacts** of TB patients being **treated for LTBI**	Proportion of **contacts** to sputum AFB smear-positive TB cases diagnosed **with latent TB infection**, who **start treatment.**		
Contacts - Timely LTBI Treatment Initiation	Proportion of **close contacts** where **assessment is completed and LTBI treatment started**, if indicated and not contraindicated or refused, **within 28 calendar days** (target 100%)	*Proportion of close contacts where assessment is completed and LTBI treatment started, if indicated and not contraindicated or refused, within 28 calendar days (target 100%)*		**Contacts are assessed** and, for those for whom prophylaxis is appropriate, the **prophylaxis is started within 28 days** of completion of contact list				
DOPT				Proportion of all **preventative therapy** that is given **by DOPT**				
Contacts - LTBI Treatment Completion	Proportion of contacts beginning treatment for LTBI who **complete treatment** (target ≥ 80%)	Of the number of **contacts starting** treatment of LTBI above (and without contraindications to INH or RMP), the **number completing treatment** at the time of reporting (**irrespective of length of treatment)** *Proportion of contacts beginning treatment for LTBI who complete treatment (target ≥ 80%)*	Proportion of close **contacts** accepting TX LTBI who **complete treatment** (< 5 years of age and ≥ 5 years of age)	Percent **completion of prophylaxis** among those **who accept**		Proportion of **contacts** to sputum AFB smear-positive TB cases who have **started treatment** for latent TB infection, **who complete treatment.**		

	PHN	FNIHB	Heffernan/Long	Fanning/Orr	WHO	USA-CDC	England	Australia
	Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
Contacts - Timely LTBI Treatment Completion		Of the number of **contacts starting** treatment of LTBI above (and without contraindications to INH or RMP), the **number completing treatment within 12 months of** treatment **initiation**						
Contacts - LTBI - Reactivation	Proportion of contacts completing treatment who show **active TB disease within two years** after completion (target < 0.5%)	*Proportion of contacts completing treatment who show active TB disease within two years after completion (target <0.5%)*						
Contacts - LTBI - Decline Treatment F/up	Proportion of contacts with **LTBI** at high risk of progression to active TB disease, but unable or **unwilling to be treated** for LTBI who have **chest radiography and sputum smear plus culture at 6, 12, and 24 months** (target ≥ 90%)	*Proportion of contacts with LTBI at high risk of progression to active TB disease, but unable or unwilling to be treated for LTBI who have chest radiography and sputum smear plus culture at 6, 12, and 24 months (target ≥ 90%)*						
Screening and Follow-up								
People with Suspected TB					Percentage of **people** with **suspected** tuberculosis **tested** using WHO recommended rapid diagnostics.			
People Living with HIV	Proportion of **HIV-positive** individuals **screened** for active TB diseases and LTBI (target 100%)	*Proportion of HIV-positive individuals screened for active TB diseases and LTBI (target 100%)*		Proportion of **HIV positive persons** that are **tested for TB infection/disease**				
People with Impaired Immunity	Proportion of individuals with **end-stage renal disease** screened for active TB diseases and LTBI (target 100%) Proportion of individuals with **transplant-related immunosuppression** screened for active TB diseases and LTBI (target 100%) Proportion of individuals with **tumor necrosis factor alpha inhibitor use** screened for active TB diseases and LTBI (target 100%) Proportion of individuals with **long-term (> 1 month) corticosteroid use** (prednisone > 15 mg/day or equivalent) screened for active TB diseases and LTBI (target ≥ 75%)	*Proportion of individuals with end-stage renal disease screened for active TB diseases and LTBI (target 100%)* *Proportion of individuals with transplant-related immunosuppression screened for active TB diseases and LTBI (target 100%)* *Proportion of individuals with tumor necrosis factor alpha inhibitor use screened for active TB diseases and LTBI (target 100%)* *Proportion of individuals with long-term (> 1 month) corticosteroid use (prednisone > 15 mg/day or equivalent) screened for active TB diseases and LTBI (target ≥ 75%)*		Proportion of **those at increased risk for TB reactivation** due to **impaired immunity** (other immunosuppressed conditions, diabetes, renal failure as defined by creatinine clearance less than 20 ml/min., immunosuppressant medication, pulmonary silicosis) are **tested for LTBI** and **assessed for** possible **preventative therapy**				
IRCC Referrals - Examination Initiation			Proportion of **IRCC referrals** who **initiate examination** within 30 days of notification			For **immigrants and refugees** with **abnormal** chest radiographs (**X-rays)** read overseas as consistent with TB, the proportion who **initiate a medical examination within 30 days of notification**.	Proportion of eligible **new entrants** covered by screening programs **who accept LTBI screening** *(*In development)*	

	PHN	FNIHB	Heffernan/Long	Fanning/Orr	WHO	USA-CDC	England	Australia
	Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
IRCC Referrals - Examination Completion	Proportion of individuals referred for **immigration medical surveillance** who (1) **keep the first appointment** with the clinic/physician **or** who have been **evaluated by public health** and (2) the relevant provincial/territorial authorities have **reported** such information **to IRCC** (target ≥ 90%)	*Proportion of individuals referred for immigration medical surveillance who (1) keep the first appointment with the clinic/physician or who have been evaluated by public health and (2) the relevant provincial/territorial authorities have reported such information to IRCC (target ≥ 90%)*	Proportion of **IRCC referrals** who **complete examination** within 90 days of notification			For **immigrants and refugees** with abnormal **chest X-rays** read overseas as consistent with TB, the proportion who **complete a medical examination within 90 days of notification**.		
IRCC Referrals - Treatment Acceptance			Proportion of **IRCC referrals recommended TX LTBI** who **accept**					
IRCC Referrals - Treatment Initiation						For **immigrants and refugees** with abnormal chest X-rays read overseas as consistent with TB who are diagnosed **with latent TB infection** or have radiographic findings consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination in the U.S., for whom **treatment** was **recommended,** the proportion **who start treatment.**		
IRCC Referrals - Treatment Completion			Proportion of **IRCC referrals accepting TX LTBI who complete**			For **immigrants and refugees** with abnormal chest X-rays read overseas as consistent with TB who are diagnosed with **latent TB infection** or have radiographic findings consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination in the U.S., and **who have started on treatment,** the proportion **who complete treatment.**	**Proportion** of (new entrant) individuals who **complete LTBI treatment amongst those who start** treatment *(*In development)*	
New Entrant LTBI Screening Initiative							The **number** of **local authorities** that have a systematic **new entrant LTBI screening initiative** in place (*In development)	
Other Programmatic								
BCG - Community		Number of **communities using BCG vaccination**						
BCG - Administered		Number of **BCG vaccinations administered**					Proportion of **babies** in areas with a universal BCG programme **who received BCG vaccine** *(*In development)*	

	PHN	**FNIHB**	**Heffernan/Long**	**Fanning/Orr**	**WHO**	**USA-CDC**	**England**	**Australia**
	Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
BCG - Eligible		Number of **births eligible to receive BCG** vaccination during reporting period						
BCG - Adverse Reactions		Number of reported **adverse reactions from BCG** **Adverse reactions from BCG:** line list of type of reaction(s) for each adverse event						
Outbreaks - New		Number of **new outbreaks** (new in the reporting period)						
Outbreaks - Ongoing		Number of **outbreaks** in [year] that were **ongoing from previous year**						
New Outbreak - Active Cases		Number of **active TB cases per new outbreak**						
Ongoing Outbreak - Active Cases		Number of **active TB cases per outbreak ongoing from previous year(s)**						
CTBRS Reporting - Completeness			Proportion of **completed** CTBRS active **TB case report forms** (last full year) Proportion of **completed CTBRS treatment outcome forms** (next to last full year)			Percent **completeness of each core Report** of Verified Case of Tuberculosis (RVCT) data item reported **to CDC**, as described in the TB cooperative agreement announcement. Percent **completeness of each core Aggregate Reports** for Tuberculosis Program Evaluation (ARPE) data items reported **to CDC**, as described in the TB cooperative agreement announcement.		**Completeness** of quarterly **reporting**.
Report Publication								Publication of a combined **notification and laboratory annual TB report** by December of the following year.
WHO Reporting								**Annual reporting to WHO.**
Global TB Elimination Activities								**Report** Australia's **participation** in **global control activities,** annually.

	PHN	FNIHB	Heffernan/Long	Fanning/Orr	WHO	USA-CDC	England	Australia
	Butler-Jones D, Corriveau A. Guidance for Tuberculosis Prevention and Control Programs in Canada. Pan-Canadian Public Heal. Netw. 2012; :1–69.	First Nations and Inuit Health Branch, Health Canada. Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-Reserve.	Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Heal 2018; 2050.	Fanning A, Orr P. TB Program Objectives and Performance Targets for FNIH Jurisdictions. 2010	World Health Organisation. The End TB Strategy. Geneva, Switzerland: 2015. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.	CDC. National TB Program Objectives & Performance Targets for 2020. 2015. https://www.cdc.gov/tb/programs/evaluation/pdf/programobjectives.pdf.	Public Health England, NHS England. Collaborative Tuberculosis Strategy for England: 2015 to 2020. 2015. www.gov.uk/government/uploads/system/uploads/attachment_data/file/396263/CollaborativeTBStrategyEngland_FINAL.pdf.	National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in Australia: 2011 – 2015. Commun Dis Intell 2012; 36:E286–E293.
Evaluation and Strategic Planning Activities		Number and brief description of TB related Inter-departmental Letter(s) of Agreement and Memoranda of Understanding in place with other federal and/or provincial government entities Number and brief description of regional policies, procedures, publications, guidelines, strategies and/or frameworks developed or adapted as required relating to TB Number and brief description of key TB working groups and committees being led or partcipated in Description of TB screening programs/policies specifying the high risk group(s) screened, method(s) of screening, etc		**Meetings** held at least **twice yearly** between all program partnership members (federal, provincial, regional, community leadership/membership) **to** review evaluation data and to **propose/discuss/ achieve improvements** All cases of **treatment failure, disease relapse**, and of **drug resistance** are **reviewed** at least **monthly** by public health and clinical experts. General **conclusions** are **shared** with partnership members. Federal, provincial, regional and community TB program partners will hold **community consultations each year**, in selected (to be agreed upon) endemic and epidemic communities in order **to report** to the people they serve **and to receive feedback** on the program.		**Number** of program **evaluation activities**, **program progress** and **evaluation status** of TB cooperative agreement recipients. The percent of TB cooperative agreement recipients who submit a **program-specific human resource development plan** (HRD) and a **yearly update of progress**, as outlined in the TB cooperative agreement announcement.		
Education - Health Provider		Number of TB knowledge transfer materials produced and/or activities engaged in (eg., poster presentations, conference presentations, publications); include a brief description of the activity including when and where it took place; for improving staff retention and knowledge		Proportion of **health care providers** working in (TB-affected) communities who have **completed an online course** specifically developed (for their) context, **regarding TB** (infection and disease) **diagnosis and therapy**. (*note - adapted to apply across population groups*)		The percent of TB cooperative agreement recipients that **have a TB training focal point.**		
Education - Community		Number of communities conducting TB-related social marketing/public education/awareness activities and a brief description of these activities		Radio, print and/or TV (e.g. DVD) **educational material** regarding TB are **available to 60% of (TB-affected) communities**. These resources are **language and culture specific**, and focus on creating a shared understanding of TB causation and elimination. (*note - adapted to apply across population groups*)				
Ethics				**Agreement** will be sought in each jurisdiction to ensure the **confidentiality of individual health data** regarding TB, while **respecting** communal **needs and rights**... within the context of their culture, traditions and legal powers. (*note - adapted to apply across population groups*)				
Determinants								
Nutrition					Percentage of population without **undernutrition**			